535
Participants
Start Date
March 7, 2024
Primary Completion Date
March 26, 2027
Study Completion Date
March 25, 2028
AMG 355
Short-term intravenous (IV) infusion
Pembrolizumab
Short-term IV infusion
RECRUITING
St Vincents Hospital Sydney, Darlinghurst
RECRUITING
The Queen Elizabeth Hospital, Woodville South
RECRUITING
Istituto Oncologico della Svizzera Italiana, Bellinzona
RECRUITING
Kantonsspital Sankt Gallen, Sankt Gallen
RECRUITING
National Taiwan University Hospital, Taipei
RECRUITING
Taipei Veterans General Hospital, Taipei
RECRUITING
Wake Forest University Health Sciences, Winston-Salem
RECRUITING
Hospital Universitario Ramon y Cajal, Madrid
RECRUITING
Institut Bergonie, Bordeaux
RECRUITING
Washington University, St Louis
COMPLETED
Alliance for Multispecialty Research - Kansas City, Merriam
RECRUITING
South Texas Accelerated Research Therapeutics, San Antonio
RECRUITING
City of Hope National Medical Center, Duarte
RECRUITING
Gustave Roussy, Villejuif
RECRUITING
Dana-Farber Cancer Institute, Boston
RECRUITING
Princess Margaret Cancer Centre, Toronto
RECRUITING
National Cancer Center Hospital East, Kashiwa-shi
RECRUITING
The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku
RECRUITING
Radboud Universitair Medisch Centrum, Nijmegen
RECRUITING
Erasmus Medisch Centrum, Rotterdam
RECRUITING
Narodowy Instytut Onkologii im Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Warsaw
RECRUITING
Seoul National University Hospital, Seoul
RECRUITING
Asan Medical Center, Seoul
RECRUITING
Hospital Universitari Vall d Hebron, Barcelona
RECRUITING
Hospital Clinic i Provincial de Barcelona, Barcelona
Lead Sponsor
Amgen
INDUSTRY